cytarabine and nsc 680410

cytarabine has been researched along with nsc 680410 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Covell, DG; Huang, R; Wallqvist, A	1
Avramis, IA; Avramis, VI; Laug, WE; Sausville, EA	1

Other Studies

2 other study(ies) available for cytarabine and nsc 680410

Article	Year
Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action. Journal of medicinal chemistry, 2006, Mar-23, Volume: 49, Issue:6 Topics: Antineoplastic Agents; Databases, Factual; Drug Screening Assays, Antitumor; Models, Statistical; National Institutes of Health (U.S.); Quantitative Structure-Activity Relationship; United States	2006
Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:4 Topics: Adamantane; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Hydroquinones; Imatinib Mesylate; Leukemia-Lymphoma, Adult T-Cell; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Vascular Endothelial Growth Factor A; Vidarabine Phosphate	2003

Article

Year

Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action.

Journal of medicinal chemistry, 2006, Mar-23, Volume: 49, Issue:6

Topics: Antineoplastic Agents; Databases, Factual; Drug Screening Assays, Antitumor; Models, Statistical; National Institutes of Health (U.S.); Quantitative Structure-Activity Relationship; United States

2006

Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.

Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:4

Topics: Adamantane; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Hydroquinones; Imatinib Mesylate; Leukemia-Lymphoma, Adult T-Cell; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Vascular Endothelial Growth Factor A; Vidarabine Phosphate

2003